OligoCalc: an online oligonucleotide properties calculator

Synthesis length : 14 kb, synthesis primer : random primer, oligo-d(T gene specific.

Is a random primer or oligo(dT) better for RT-PCR reaction?

This article by Eugene Lukhtanov of ELITechGroup Molecular Diagnostics introduces the tripeptide of dihydropyrroloindole-carboxylate (CDPI3), which is a minor groove binding (MGB) moiety derived from the natural product CC-1065 and exhibits strong DNA binding properties. Synthetic oligonucleotides with covalently-attached CDPI3 moieties have enhanced DNA affinity and have improved the hybridization properties of sequence-specific DNA probes. Short CDPI3-oligonucleotides hybridize with single-stranded DNA to give more stable DNA duplexes than unmodified oligonucleotides of similar length. The author describes the general properties of CDPI3 MGB-oligonucleotide conjugates in detail, along with some specific applications:

Induced cross-linking reactions to target genes using modified oligonucleotides

Is a random primer or oligo(dT) ..

The master mix reagent (5x) contains the highly efficient reverse transcriptase "ReverTra Ace®" , primers and buffer optimized for highly efficient synthesis of short-chain cDNAs suitable for real-time PCR.

Formation of N-branched oligonucleotides as by-products in solid-phase oligonucleotide synthesis

The specially formulated reaction buffer contains oligo dT and random hexamers and provides unbiased representation and equivalent cDNA abundance over a wide range of input RNA.

Purify mRNA with the mRNA oligotex minikit (Ambion) according to manufacturer's instructions.

of anchored oligo(dT) primers for cDNA synthesis

In this article, we introduce 5'-CDPI3 MGB™ Phosphoramidite and 3'-CDPI3 MGB™ CPG. Specific instructions are provided for the use of these products and the procedures are illustrated using HPLC and MS data. Details of a melting study using a CDPI3 MGB-oligonucleotide conjugate are presented.

Oligo-dT Primers - QIAGEN Online Shop

Phosphoramidites that allow the generation of oligonucleotides containing site-specific lesions have been vital components for studying the mechanism of DNA repair. New DNA lesions are still being discovered and the study of their biological consequences will require their site-specific incorporation into oligonucleotides. The authors conclude that the increased availability of phosphoramidites for the synthesis of lesion-containing oligonucleotides should facilitate many future discoveries in the broad area of DNA damage and repair.

DNA & RNA & ZNA Oligonucelotide Synthesis | …

The PrimeScript First Strand cDNA Synthesis Kit contains all of the reagents necessary for synthesis of first-strand cDNA from total or poly(A)+ RNA using PrimeScript Reverse Transcriptase. Choose this cDNA synthesis kit when you want to synthesize full-length cDNA with provided primers (select from oligo dT or random 6-mer primers, both included in the kit.) This cDNA synthesis kit is powered by PrimeScript Reverse Transcriptase, which has exceptionally strong strand displacement activity and efficiently synthesizes cDNA. PrimeScript RTase is robust, versatile and well-suited for applications requiring full-length cDNA such as cDNA library construction. This PrimeScript-based cDNA synthesis kit also works well with other cDNA-dependent techniques including RT-PCR, cDNA probe preparation and real-time quantitative RT-PCR (qRT-PCR or RT-qPCR). The PrimeScript First Strand cDNA Synthesis Kit is ideal for reverse transcription of many different RNA templates, including GC-rich templates and RNAs with high levels of secondary structure.

DNA & RNA Oligonucleotides - Quality You Can Trust

A directed approach to the delivery of therapeutic oligonucleotides specifically to the liver has been to target the asialoglycoprotein receptor (ASGPR) using a suitable glycoconjugate. Indeed, ASGPR is the ideal target for delivery of therapeutic oligonucleotides to the liver since it combines tissue specificity, high expression levels and rapid internalization and turnover. The use of oligonucleotide glycoconjugates has led to significant advances in therapeutic delivery as evidenced by the work of Alnylam Pharmaceuticals and Ionis Pharmaceuticals using multivalent N-acetylgalactosamine (GalNAc) oligonucleotide conjugates.